Short answer: probably not enough to change your treatment plan. An updated Cochrane review of 21 studies in 1,634 women with polycystic ovary syndrome (PCOS) finds myo-inositol may slightly raise the chance of getting pregnant through IVF — but the evidence does not show it helps women actually have a baby.
That distinction matters, because “getting pregnant” and “having a baby” are different outcomes, and supplement marketing often blurs them. The review, led by Marian G Showell, Rebecca Mackenzie-Proctor, Vanessa Jordan et al. (5 authors) at the University of Auckland, Department of Obstetrics and Gynaecology and Auckland City Hospital, Department of Obstetrics and Gynaecology, updates a previous review published in 2018, with evidence current to 10 November 2025, cochrane.org reported.
Myo-inositol shows limited impact on pregnancy and live birth rates
- If you are trying to conceive naturally or with ovulation induction or insemination, the review found no reliable evidence that myo-inositol improves your chances of pregnancy or live birth.
- If you are undergoing IVF, myo-inositol may slightly improve ultrasound-confirmed pregnancy rates — but the same review could not confirm any improvement in live birth rates.
- The reviewers themselves say they are “unsure” on nearly every outcome that matters most to women, including miscarriage and multiple pregnancy.
Can inositol help you have a baby?
On the outcome women care about most — a live birth — the reviewers’ answer is uncertainty. In women with PCOS undergoing IVF, they are unsure whether myo-inositol, compared with no treatment, affects the chances of having a baby (2 studies, 84 women) or of losing a pregnancy (also 2 studies, 84 women), cochrane.org reported.
Pregnancy was a slightly different story. Across 3 studies including 164 women having IVF, myo-inositol may slightly improve the chance of getting pregnant, confirmed by ultrasound. Against an expected pregnancy rate of 15% with no treatment, the reviewers calculated that the chance with myo-inositol may range from 15% to 46%.
That range is wide, and it captures the problem: the lower bound is no benefit at all. In the review’s own framing, compared with routine treatment (folic acid), myo-inositol “may increase slightly the chances of getting pregnant (confirmed by ultrasound), but not necessarily the chances of having a baby.”
What did the 21 studies actually test?
The review pooled 21 studies involving 1,634 women with PCOS, carried out in Iran, India, Italy, Albania, Germany, and Vietnam. All the women were receiving routine pre-pregnancy care. Most studies examined myo-inositol; a handful looked at a second form, D-chiro-inositol, but did not report results the reviewers could use.
The comparisons varied. One study of 120 women covered ovulation induction (medicines that help the ovaries release eggs) or intrauterine insemination (prepared sperm placed directly into the womb around ovulation). Another single study of 102 women pitted myo-inositol against metformin (a pill that helps to lower blood sugar, commonly used for PCOS). On live birth, pregnancy, miscarriage and ovarian hyperstimulation syndrome, the reviewers were unsure what that metformin comparison showed.
| Outcome | Comparison | Evidence base | Reviewers’ conclusion |
|---|---|---|---|
| Pregnancy (ultrasound-confirmed) | Myo-inositol vs no treatment, IVF | 3 studies, 164 women | May improve slightly; 15% expected, range 15–46% |
| Having a baby | Myo-inositol vs no treatment, IVF | 2 studies, 84 women | Unsure |
| Losing a pregnancy | Myo-inositol vs no treatment, IVF | 2 studies, 84 women | Unsure |
| Multiple pregnancy | Myo-inositol vs no treatment, IVF | 1 study, 34 women | Unsure |
| Pregnancy and live birth | Myo-inositol vs no treatment, ovulation induction or IUI | 1 study, 120 women | Unsure |
| Live birth and pregnancy | Myo-inositol vs metformin, IVF | 1 study, 102 women | Unsure |
Why does the evidence stay so weak?
The reviewers list three reasons they are not confident. Some studies included few women. Some reported few events — few pregnancies, few miscarriages — which makes statistics unreliable. And some had weaknesses in their design, meaning the way women were assigned to treatment groups or outcomes measured could bias the results.
There is also a reporting gap. Some studies did not report the outcomes that matter most to women: having a baby, losing a pregnancy, or unwanted effects of treatment. A supplement trial that measures only hormone levels or egg counts cannot tell a patient whether the supplement helps her deliver a child.
How would inositol work in PCOS?
The biological rationale is plausible, which is why the research exists at all. Inositol is a natural substance found in foods such as fruit, nuts, and beans, and the body also makes it from sugar.
Early research suggests it may help the body use insulin better — and insulin resistance is considered a key factor in the metabolic and reproductive features of PCOS, according to the clinical background published on the Cochrane Library.
The proposed chain runs like this: better insulin sensitivity may improve hormone balance, and better hormone balance may help the ovary develop and release eggs — the step that fails in many women with PCOS, who may not ovulate regularly because of a hormone imbalance.
How common is PCOS, really?
Here the two Cochrane sources differ, and it is worth saying so plainly. Cochrane’s plain-language summary puts the condition at about one in eight women worldwide. The Cochrane Library’s clinical background gives a figure of 6% to 10% of women in the reproductive age group, rising as high as 15% when the broader Rotterdam criteria are applied. Both descriptions fit the same condition; the gap reflects different counting methods, not different facts.
The condition causes irregular periods, extra hair growth or hair loss, weight gain, difficulty getting pregnant and mood problems. About half of those with PCOS are obese, and the Cochrane Library points out that this figure varies by region — the USA and Australia show the highest levels of obesity, with 61% to 76% of women with PCOS there classed as obese.
There is no cure, but treatments and lifestyle changes can help with symptoms. Cochrane’s summary also notes the condition, which was renamed polyendocrine metabolic ovarian syndrome (PMOS) in 2026.
Who funded the research — and who wrote it?
The review’s authors are affiliated with the University of Auckland’s Department of Obstetrics and Gynaecology at Park Road Grafton Auckland New Zealand 1142, and with Auckland City Hospital’s Department of Obstetrics and Gynaecology at Auckland New Zealand 1142. The material published alongside the review does not report funding from any supplement manufacturer; inositol is widely available as a dietary supplement, and the body also makes it from sugar.
That commercial context is exactly why the reviewers’ caution carries weight. The demand for a signal — any signal — is strong, and this review declines to supply one beyond a modest, low-certainty pregnancy finding in IVF patients.
Consult fertility specialists regarding myo-inositol safety and interactions
The review did not report clear evidence of harm from myo-inositol, but it also did not establish safety with confidence: unwanted effects of treatment were among the outcomes some studies failed to report.
Women with PCOS who are trying to conceive should discuss any supplement with their fertility specialist before starting it, particularly if they are already taking metformin or undergoing ovulation induction, IVF, or insemination, where supplement–drug interactions and protocol changes are decisions for the treating clinician.
Anyone with PCOS who experiences worsening symptoms — prolonged absence of periods, rapid weight gain, signs of raised blood sugar, or mood changes — should seek medical review rather than self-treating. And because the reviewers flagged ovarian hyperstimulation syndrome and gestational diabetes as outcomes the evidence could not address, patients on fertility treatment should report symptoms of over-stimulated ovaries or abnormal blood sugar in pregnancy to their care team promptly.
What has to happen before the answer changes?
The reviewers are specific about the gap. Higher-quality research is required to determine whether the two forms of inositol (myo-inositol and D-chiro-inositol) can safely help women with PCOS achieve pregnancy. Those studies should cover different stages of fertility treatment and also include women trying to get pregnant naturally, a group the current evidence base barely touches.
Until such trials exist, the review’s bottom line for the 1,634 women whose data it examined stands: a possible small boost to IVF pregnancy rates, uncertainty about everything else, and an evidence cutoff that the reviewers set at 10 November 2025.
References
- Showell MG, Mackenzie-Proctor R, Jordan V, et al. “Inositol for subfertile women with polycystic ovary syndrome.” Cochrane Database of Systematic Reviews, 2018. Cochrane Database of Systematic Reviews
- Cochrane Library. “Inositol for subfertile women with polycystic ovary syndrome.”
- Cochrane (cochrane.org). Plain-language summary of the updated review, “Inositol for subfertile women with polycystic ovary syndrome,” evidence current to 10 November 2025.